Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma

Blood

Volumn 126, Issue 26, 2015, Pages 2821-2831

  Dai, Lu ^a,b   Trillo Tinoco, Jimena ^a   Cao, Yueyu ^b   Bonstaff, Karlie ^a   Doyle, Lisa ^a   Valle, Luis Del ^a   Whitby, Denise ^c   Parsons, Chris ^a   Reiss, Krzysztof ^a   Zabaleta, Jovanny ^a   Qin, Zhiqiang ^a,b  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^c FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CRIZOTINIB; CYCLIN A2; CYCLIN B1; CYCLIN DEPENDENT KINASE 2; HISTONE H2AX; PROTEIN P53; RETINOBLASTOMA PROTEIN; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE; RIBONUCLEOSIDE DIPHOSPHATE REDUCTASE SUBUNIT M2; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; HGF PROTEIN, HUMAN; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFECT; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 8; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROARRAY ANALYSIS; MOUSE; MOUSE MODEL; NONHUMAN; OUTCOME ASSESSMENT; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT; UPREGULATION; VIRUS CARCINOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; COMET ASSAY; COMPLICATION; DNA MICROARRAY; DRUG EFFECTS; DRUG SCREENING; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HERPES VIRUS INFECTION; IMMUNOBLOTTING; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; SIGNAL TRANSDUCTION; YOUNG ADULT;

ADULT; ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; COMET ASSAY; DNA DAMAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATOCYTE GROWTH FACTOR; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HUMANS; IMMUNOBLOTTING; IMMUNOCOMPROMISED HOST; LYMPHOMA, PRIMARY EFFUSION; MALE; MICE; MICE, SCID; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PIPERIDINES; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS; YOUNG ADULT;

EID: 84955151649     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-07-658823     Document Type: Article

References (56)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332(18):1186-1191.
2. Carbone A, Cesarman E, Gloghini A, Drexler HG. Understanding pathogenetic aspects and clinical presentation of primary effusion lymphoma through its derived cell lines. AIDS. 2010;24(4): 479-490.
3. Carbone A, Gloghini A, Vaccher E, et al. Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive solid lymphomas: a tissue-based variant of primary effusion lymphoma. J Mol Diagn. 2005;7(1):17-27.
4. Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM. KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol. 2004;28(11):1401-1416.
5. Chen YB, Rahemtullah A, Hochberg E. Primary effusion lymphoma. Oncologist. 2007;12(5): 569-576.
6. Carbone A, Gloghini A. KSHV/HHV8-associated lymphomas. Br J Haematol. 2008;140(1):13-24.
7. Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311(5981):29-33.
8. Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802-804.
9. Organ SL, Tsao MS. An overview of the c-MET signaling pathway. Ther Adv Med Oncol. 2011; 3(suppl 1):S7-S19.
10. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol. 2010;11(12):834-848.
11. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316(5827):1039-1043.
12. Sulpice E, Ding S, Muscatelli-Groux B, et al. Cross-talk between the VEGF-A and HGF signalling pathways in endothelial cells. Biol Cell. 2009;101(9):525-539.
13. Vermeulen L, De Sousa E, Melo F, van der Heijden M, et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol. 2010;12(5): 468-476.
14. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89-103.
15. Sierra JR, Tsao MS. c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol. 2011;3(suppl 1):S21-S35.
16. Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res. 2009;15(7):2207-2214.
17. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov. 2008;7(6):504-516.
18. Toschi L, Jänne PA. Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. Clin Cancer Res. 2008;14(19):5941-5946.
19. Capello D, Gaidano G, Gallicchio M, et al. The tyrosine kinase receptor met and its ligand HGF are co-expressed and functionally active in HHV-8 positive primary effusion lymphoma. Leukemia. 2000;14(2):285-291.
20. Kawano R, Ohshima K, Karube K, et al. Prognostic significance of hepatocyte growth factor and c-MET expression in patients with diffuse large B-cell lymphoma. Br J Haematol. 2004;127(3):305-307.
21. Teofili L, Di Febo AL, Pierconti F, et al. Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood. 2001;97(4):1063-1069.
22. Dai L, Trillo-Tinoco J, Bai L, et al. Systematic analysis of a xenograft mice model for KSHV1 primary effusion lymphoma (PEL). PLoS One. 2014;9(2):e90349.
23. Samols MA, Hu J, Skalsky RL, Renne R. Cloning and identification of a microRNA cluster within the latency-associated region of Kaposi's sarcomaassociated herpesvirus. J Virol. 2005;79(14): 9301-9305.
24. Adang LA, Tomescu C, Law WK, Kedes DH. Intracellular Kaposi's sarcoma-associated herpesvirus load determines early loss of immune synapse components. J Virol. 2007;81(10): 5079-5090.
25. Mbisa GL, Miley W, Gamache CJ, et al. Detection of antibodies to Kaposi's sarcoma-associated herpesvirus: a new approach using K8.1 ELISA and a newly developed recombinant LANA ELISA. J Immunol Methods. 2010;356(1-2):39-46.
26. Benavente Y, Mbisa G, Labo N, et al. Antibodies against lytic and latent Kaposi's sarcomaassociated herpes virus antigens and lymphoma in the European EpiLymph case-control study. Br J Cancer. 2011;105(11):1768-1771.
27. Workman C, Jensen LJ, Jarmer H, et al. A new non-linear normalization method for reducing variability in DNA microarray experiments. Genome Biol. 2002;3(9):research0048.
28. Dai L, Cao Y, Chen Y, Kaleeba JA, Zabaleta J, Qin Z. Genomic analysis of xCT-mediated regulatory network: Identification of novel targets against AIDS-associated lymphoma. Oncotarget. 2015;6(14):12710-12722.
29. Kim SH, Sierra RA, McGee DJ, Zabaleta J. Transcriptional profiling of gastric epithelial cells infected with wild type or arginase-deficient Helicobacter pylori. BMC Microbiol. 2012;12:175.
30. Dai L, Cao Y, Chen Y, Parsons C, Qin Z. Targeting xCT, a cystine-glutamate transporter induces apoptosis and tumor regression for KSHV/HIV-associated lymphoma. J Hematol Oncol. 2014;7:30.
31. Qin Z, Dai L, Trillo-Tinoco J, et al. Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma. Mol Cancer Ther. 2014;13(1): 154-164.
32. Baldus SE, Engelmann K, Hanisch FG. MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci. 2004;41(2):189-231.
33. Woenckhaus M, Merk J, Stoehr R, et al. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer. Hum Pathol. 2008;39(1):126-136.
34. Schroeder JA, Masri AA, Adriance MC, et al. MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene. 2004;23(34): 5739-5747.
35. Kufe DW. MUC1-C oncoprotein as a target in breast cancer: activation of signaling pathways and therapeutic approaches. Oncogene. 2013; 32(9):1073-1081.
36. Zhou B, Su L, Hu S, et al. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance. Cancer Res. 2013; 73(21):6484-6493.
37. Larsson A, Stenberg K, Ericson AC, et al. Mode of action, toxicity, pharmacokinetics, and efficacy of some new antiherpesvirus guanosine analogs related to buciclovir. Antimicrob Agents Chemother. 1986;30(4):598-605.
38. Shao J, Zhou B, Zhu L, et al. Determination of the potency and subunit-selectivity of ribonucleotide reductase inhibitors with a recombinant-holoenzyme-based in vitro assay. Biochem Pharmacol. 2005;69(4):627-634.
39. Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic largecell lymphoma. Mol Cancer Ther. 2007;6(12 Pt 1): 3314-3322.
40. Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015; 112(11):3493-3498.
41. Stella GM, Benvenuti S, Gramaglia D, et al. MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat. 2011;32(1):44-50.
42. Seiwert TY, Jagadeeswaran R, Faoro L, et al. The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma. Cancer Res. 2009;69(7): 3021-3031.
43. Ma PC, Tretiakova MS, MacKinnon AC, et al. Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 2008;47(12):1025-1037.
44. Giordano S, Maffe A, Williams TA, et al. Different point mutations in the met oncogene elicit distinct biological properties. FASEB J. 2000;14(2): 399-406.
45. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene. 2000;19(43):4947-4953.
46. Park WS, Dong SM, Kim SY, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999;59(2):307-310.
47. Lutterbach B, Zeng Q, Davis LJ, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 2007;67(5):2081-2088.
48. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res. 2006;66(1):283-289.
49. Peschard P, Fournier TM, Lamorte L, et al. Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell. 2001;8(5): 995-1004.
50. Vigna E, Gramaglia D, Longati P, Bardelli A, Comoglio PM. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET. Oncogene. 1999;18(29):4275-4281.
51. Singh VV, Dutta D, Ansari MA, Dutta S, Chandran B. Kaposi's sarcoma-associated herpesvirus induces the ATM and H2AX DNA damage response early during de novo infection of primary endothelial cells, which play roles in latency establishment. J Virol. 2014;88(5):2821-2834.
52. Hollingworth R, Skalka GL, Stewart GS, Hislop AD, Blackbourn DJ, Grand RJ. Activation of DNA Damage Response Pathways during Lytic Replication of KSHV. Viruses. 2015;7(6): 2908-2927.
53. Kunos CA, Radivoyevitch T, Pink J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. 2010;174(5):574-581.
54. Kunos CA, Radivoyevitch T, Waggoner S, et al. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol. 2013;130(1):75-80.
55. Chao J, Synold TW, Morgan RJ Jr, et al. A phase I and pharmacokinetic study of oral 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in the treatment of advanced-stage solid cancers: a California Cancer Consortium Study. Cancer Chemother Pharmacol. 2012;69(3):835-843.
56. Yen Y, Margolin K, Doroshow J, et al. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol. 2004;54(4): 331-342.